Status:
UNKNOWN
Cellular-Mediated Immunity in COVID-19
Lead Sponsor:
University of Campania Luigi Vanvitelli
Conditions:
Covid19
Thromboembolism
Eligibility:
All Genders
18+ years
Brief Summary
In order to prevent reinfection, it is needed to detect the cellular-mediated immune response to the Sars-CoV-2 infection. The first goal of this study will be to detect the cellular-mediated immune r...
Detailed Description
First goal: Characterization of the immune response using detailed phenotypic evaluation of the adaptive compartment comprising B, T, and NK cells. The Investigators aim is to detect the cellular-medi...
Eligibility Criteria
Inclusion
- Age \> 18 years
- Previous diagnosis of COVID-19
- Absence of COVID-19 diagnosis
Exclusion
- Age \<18 years
- Inflammatory diseases
Key Trial Info
Start Date :
March 14 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 14 2022
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT04746521
Start Date
March 14 2021
End Date
December 14 2022
Last Update
February 14 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
U.O.C. Division of Clinical Immunology, Immunohematology, Transfusion Medicine and Transplant Immunology, Regional Reference Laboratory of Transplant Immunology, Department of Internal and Specialty Medicine, A.O.U., UniversityofCampania "Luigi Vanvitelli
Napoli, Italy, 80138